Grace Therapeutics, Inc. Common Stock GRCE
HEALTHCARE · BIOTECHNOLOGYi
Market datapartial · fetched 2026-11-19T20:26:05.723Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-02-19
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-19T20:00:48.163562545Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-19T20:26:04.600500+00:00
Grace Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.69 | 453.1% | 65.7% | |||
| 25Δ | 2.87 | 429.7% | 60.7% | |||
| 30Δ | 3.05 | 406.2% | 55.7% | |||
| 35Δ | 3.22 | 382.8% | 50.7% | |||
| 40Δ | 3.40 | 359.4% | 45.7% | |||
| 45Δ | 3.58 | 336.0% | 40.8% | |||
| 50Δ | 3.76 | 312.6% | 35.8% | |||
| 55Δ | 3.94 | 289.2% | 30.8% | |||
| 60Δ | 4.12 | 265.8% | 25.8% | |||
| 65Δ | 4.30 | 242.4% | 20.8% | |||
| 70Δ | 4.47 | 219.0% | 15.8% | |||
| 75Δ | 4.65 | 195.6% | 10.9% | |||
| 80Δ | 4.83 | 172.2% | 5.9% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.69
- IV
- 453.1%
- B/E move
- 65.7%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.87
- IV
- 429.7%
- B/E move
- 60.7%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.05
- IV
- 406.2%
- B/E move
- 55.7%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.22
- IV
- 382.8%
- B/E move
- 50.7%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.40
- IV
- 359.4%
- B/E move
- 45.7%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.58
- IV
- 336.0%
- B/E move
- 40.8%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.76
- IV
- 312.6%
- B/E move
- 35.8%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.94
- IV
- 289.2%
- B/E move
- 30.8%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.12
- IV
- 265.8%
- B/E move
- 25.8%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.30
- IV
- 242.4%
- B/E move
- 20.8%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.47
- IV
- 219.0%
- B/E move
- 15.8%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.65
- IV
- 195.6%
- B/E move
- 10.9%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.83
- IV
- 172.2%
- B/E move
- 5.9%
Options history
History unavailable
Biotechnology
GYRE
Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. Leveraging its proprietary…
More →HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is…
More →HELP
Description unavailable
More →HOWL
Description unavailable
More →HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is…
More →HUMA
Description unavailable
More →